NFA
HRTX icon

Nationwide Fund Advisors’s Heron Therapeutics HRTX Stock Holding History

Nationwide Fund Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,154
Closed -$406K – 946
2017
Q3 		$406K Sell
25,154
-681
-3% -$10.7K ﹤0.01% 2286
2017
Q2 		$358K Buy
25,835
+3,863
+18% +$56K ﹤0.01% 2347
2017
Q1 		$330K Buy
21,972
+2,233
+11% +$30.9K ﹤0.01% 2372
2016
Q4 		$259K Sell
19,739
-991
-5% -$15.5K ﹤0.01% 2494
2016
Q3 		$357K Hold
20,730
– – ﹤0.01% 2338
2016
Q2 		$374K Buy
20,730
+1,920
+10% +$37.5K ﹤0.01% 2304
2016
Q1 		$357K Sell
18,810
-405
-2% -$7.99K ﹤0.01% 2266
2015
Q4 		$513K Buy
19,215
+508
+3% +$13.6K ﹤0.01% 2108
2015
Q3 		$456K Buy
18,707
+2,708
+17% +$90.2K ﹤0.01% 2169
2015
Q2 		$499K Sell
15,999
-937
-6% -$17.6K ﹤0.01% 2247
2015
Q1 		$246K Sell
16,936
-661
-4% -$7.45K ﹤0.01% 2591
2014
Q4 		$177K Hold
17,597
– – ﹤0.01% 2692
2014
Q3 		$147K Buy
17,597
+3,183
+22% +$29.6K ﹤0.01% 2842
2014
Q2 		$178K Buy
+14,414
New +$172K ﹤0.01% 2808

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Nationwide Fund Advisors's HRTX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Heron Therapeutics (HRTX) in Q4 2017, closing a stake of 25,154 shares — an estimated $406K sold.

Nationwide Fund Advisors first reported a position in HRTX in Q2 2014 and held it in 14 quarters. The position peaked at $513K in Q4 2015. 124 funds tracked by Wall St. Rank hold HRTX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Heron Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 25,154 Heron Therapeutics shares in Q4 2017, an estimated $406K.
  • Nationwide Fund Advisors first reported a position in Heron Therapeutics in Q2 2014 and held it in 14 quarters.
  • Nationwide Fund Advisors's Heron Therapeutics position peaked at $513K in Q4 2015.
  • 124 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.